Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: gene-activated interferon beta - Takeda

Drug Profile

Research programme: gene-activated interferon beta - Takeda

Alternative Names: GA-INFβ; Gene-activated interferon beta research programme - Takeda; Gene-activated β-Ifn; Research programme: gene-activated interferon beta - Transkaryotic Therapies

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Gene therapies; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 19 Mar 2010 Gene-Activated interferon beta is available for licensing as of 19 Mar 2010. http://www.shire.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top